Novartis Projects Steady Long-Term Sales Growth Powered by Upgraded Blockbuster Drugs
Basel, Thursday, 19 November 2026.
Novartis projects 5% annual sales growth through 2031 and raised peak sales targets across key medicines, aiming to overcome the company’s largest patent cliff in history.
Updated Long-Term Financial Outlook
Novartis AG (NYSE: NVS) has revised its medium-term financial outlook, projecting a compound annual net sales growth rate of 5% at constant exchange rates from 2026 through 2031 [1][3][8][10]. The updated guidance, unveiled during an investor event in London on 19 November 2026, underscores the company’s confidence in its ability to navigate the most significant loss-of-exclusivity (LOE) impact in its history, expected to peak in 2026 [1][3][8][10]. Novartis also anticipates a return to a core operating income margin of 40% or higher by 2029, a target aligned with its strategic focus on margin expansion and operational efficiency [1][3][8][10].
Blockbuster Drugs Drive Growth Ambitions
At the heart of Novartis’s upgraded sales projections are nine in-market assets, each with peak sales potential ranging from $3 billion to $10 billion. Key drugs such as Kisqali, Rhapsido, Cosentyx, Kesimpta, Pluvicto, Scemblix, Leqvio, the Zolgensma group (Zolgensma and Itvisma), and Fabhalta are expected to underpin the company’s growth trajectory [1][3][8][10]. The company has raised its peak sales guidance for several of these blockbusters: Kesimpta’s target was increased from $6 billion to $8 billion, Scemblix from $4 billion to $5 billion, and Leqvio from $4 billion to $5 billion [1][3][8][10]. Additionally, Rhapsido’s peak sales guidance was recently upgraded to $8 billion [1][3][8][10].
Pipeline Strength and Strategic Focus
Novartis is banking on a robust pipeline of over 30 high-potential assets across four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience, and oncology [2][3]. More than 20 of these pipeline assets are in late-stage development, including registration, Phase II, or Phase III trials, with over 10 expected to achieve multi-billion-dollar peak sales [2][3]. The company expects more than 35 potentially submission-enabling trial readouts through 2031, providing a steady stream of regulatory catalysts [1][3][8][10]. Highlighted pipeline programs include abelacimab for stroke prevention in atrial fibrillation, pelabresib for myelofibrosis, and 225Ac-PSMA-617 for prostate cancer, among others [2][3][8][10].
Market and Analyst Reactions
Analysts have responded cautiously to Novartis’s updated outlook. Jefferies acknowledged that the higher growth forecasts for key drugs like Kesimpta, Scemblix, and Leqvio strengthen the company’s growth outlook and reduce some risks associated with achieving these targets [1]. However, the bank noted that longer-term ambitions still rely heavily on assets such as pacibekitug and del-desiran, which face uncertainties following recent trial results [1]. Jefferies maintained a Hold rating on Novartis with a 125 Swiss franc price target [1]. Citigroup, on the other hand, cited forecasts above consensus, projecting a 5% compound annual sales growth rate from 2026 to 2031 compared to the 4.2% expected by analysts [1]. Despite this optimism, Citigroup expressed skepticism about growth prospects beyond 2031, pending further data on pipeline assets [1]. The bank maintained a Buy rating with a 150 Swiss franc price target [1].
Risks and Uncertainties
Novartis’s long-term growth strategy is not without risks. The company faces ongoing challenges such as global healthcare cost containment, government pricing pressures, and reimbursement requirements, which could impact its financial performance [4][5][8]. Additionally, the company’s ability to maintain intellectual property and patent protection for key products is a critical factor in sustaining its growth momentum [4][5][8]. Operational risks include the adoption of artificial intelligence and new technologies, information security breaches, legal proceedings, regulatory delays, and manufacturing issues [4][5][8]. External factors such as macroeconomic developments, geopolitical tensions, and potential tariffs on products also pose risks to Novartis’s operations and financial outlook [4][5][8].
Corporate Responsibility and Social Impact
Beyond its financial outlook, Novartis continues to emphasize its commitment to corporate responsibility. In November 2026, the company was ranked first in the Access to Medicine Index for the second consecutive time, achieving an overall score of 3.86 out of 5 [6]. This recognition highlights Novartis’s efforts to expand access to healthcare, particularly in low- and middle-income countries [6]. The company has reached 304 million patients globally, including 30 million through access approaches and 7.3 million through its Sub-Saharan Africa Business Unit [6]. Novartis has also invested over $500 million in R&D for global health since 2021, targeting diseases such as malaria, dengue, leishmaniasis, and Chagas disease [6].
Sources
- ca.marketscreener.com
- www.novartis.com
- www.novartis.com
- www.novartis.com
- www.tradingview.com
- www.novartis.com
- mlq.ai
- finance.biggo.com
- www.globalbankingandfinance.com
- www.novartis.com